Cagrilintide 5mg
Size: 5mg | 99% Purity
M.Wt: 4577.5
Solubility: H2O
Purity: >99%
Storage: -20°C / 3 years
Half life: ~7 days
CAS No.: 1415456-99-3
| Purity (HPLC) | >99% |
|---|---|
| Molecular weight | 4577.5 g/mol |
| CAS number | 1415456-99-3 |
| Synonyms | Cagrilintide, AM833 |
| Solubility | H2O |
| Storage | -20°C / 3 years |
| Half-life | ~7 days |
HPLC and MS verified by UKAS-accredited laboratories.
Royal Mail 24 and DPD Next Day options.
COA and batch number on every vial.
Description
Size: 5mg | 99% Purity
M.Wt: 4577.5
Solubility: H2O
Purity: >99%
Storage: -20°C / 3 years
Half life: ~7 days
CAS No.: 1415456-99-3
*(This is a lyophilised powder and will need reconstitution — Sterile Water for reconstitution is supplied separately.)
Reconstitution
For peptides supplied as lyophilised powder, reconstitute in bacteriostatic water or sterile saline at the concentration appropriate to your protocol. Allow the vial to come to room temperature before opening, add solvent slowly down the inside wall (do not directly onto the powder), and gently invert until clear. Do not vortex.
Reconstituted solutions are typically stable at 2–8°C for the durations published in the corresponding peer-reviewed reference. For long-term storage, aliquot and freeze at −20°C; avoid repeated freeze–thaw cycles.
Research literature
Selected peer-reviewed publications from PubMed referencing this compound. Provided for research orientation — not an endorsement of any clinical application. Each citation links to the canonical PubMed record.
-
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey WT et al. · The New England journal of medicine · 2025
PubMed PMID 40544433 -
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Davies MJ et al. · The New England journal of medicine · 2025
PubMed PMID 40544432 -
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW et al. · Lancet (London, England) · 2021
PubMed PMID 34798060
You may also need
Related compounds
